Shopping Cart
- Remove All
Your shopping cart is currently empty
EMD57033 is a cardiac troponin C (cTnC) activator, a dominant Ca2+ sensitizer, which functions by binding to cardiac/slow skeletal troponin C heterodimers to promote cardiac contraction.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $318 | In Stock | |
| 5 mg | $753 | In Stock | |
| 10 mg | $987 | In Stock | |
| 25 mg | $1,530 | In Stock | |
| 50 mg | $1,980 | In Stock | |
| 100 mg | $2,500 | In Stock |
| Description | EMD57033 is a cardiac troponin C (cTnC) activator, a dominant Ca2+ sensitizer, which functions by binding to cardiac/slow skeletal troponin C heterodimers to promote cardiac contraction. |
| In vitro | EMD57033 (5.0 to 5.8 mumol/L) enhances contractility and prolongs relaxation. Its effects are modulated by heart rate, [Ca2+]o, and contraction mode, with positive inotropic effects being more prominent for ejecting beats.[4] |
| In vivo | EMD-57033 (0.4 mg. kg(-1). min(-1) for 20 minutes) selective Ca(2+) sensitization with minimal PDE3I in vivo is achieved, improving basal and rate-stimulated contractility and mechanoenergetics of HF without compromising diastolic function. Despite PDE3I activity at higher doses, energetic benefits persist.[5] |
| Synonyms | EMD-57033, EMD 57033, (+)-EMD 57033 |
| Molecular Weight | 425.5 |
| Formula | C22H23N3O4S |
| Cas No. | 147527-31-9 |
| Smiles | O=C(C1=CC(OC)=C(C=C1)OC)N2C3=CC=C(C([C@H](S4)C)=NNC4=O)C=C3CCC2 |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (117.51 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.